Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

NCT02900716 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
B-Cell Lymphoma

Interventions

DRUG: DTRMWXHS-12
DRUG: DTRM-505
DRUG: DTRM-555

Sponsor

Zhejiang DTRM Biopharma